Abingdon Health
ABDX · AIM · Health Care · mcap £29m · 10.8p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 07 Oct 26 | Routine | Notice of Results | |
| 29 Sep 26 | UKAS ISO/IEC 17025 accreditation
York, UK and Madison, WI, USA, 29 September 2026: Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and provider of regulatory services for rapid diagnostic tests and med-tec |
+4.8% | |
| 25 Sep 26 | Official opening of manufacturing hub in the US
Official opening of manufacturing hub in the US |
+0.0% | |
| 08 Sep 26 | Shareholder open day
York, UK and Madison, WI, USA, 8 September 2026: Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, a |
+0.0% | |
| 29 Jul 26 | Trading update | Trading update
31% increase in full year revenues and progression to EBITDA profitability in H2 |
+4.1% |
| 29 May 26 | Presentation at Mello2026
York, UK and Madison, WI, USA, 29 May 2026: Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announ |
+0.0% | |
| 27 May 26 | US tax credit agreement
York, UK and Madison, WI, USA, 27 May 2026: Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announ |
−2.1% | |
| 19 May 26 | Earn-out Consideration and Issue of Equity
York, UK and Madison, WI, USA, 19 May 2026: Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announ |
−4.2% | |
| 11 May 26 | Launch of LVOne Stroke Test by UpFront Diagnostics
UK Launch of LVOne Stroke Triage Test by UpFront Diagnostics |
+4.2% | |
| 07 May 26 | Holding | Holding(s) in Company | |
| 06 May 26 | Update on Partnership with 4TEEN4 Pharmaceuticals
York, UK and Madison, WI, USA, 6 May 2026: Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, provide |
+6.4% | |
| 21 Apr 26 | Routine | Admission to trading on OTCQB in the US | |
| 15 Apr 26 | EMI Share Option Scheme
15 April 2026: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces that it has allocated a total of 3,096,0 |
+0.0% | |
| 14 Apr 26 | Trading to commence on the OTCQB in the US
Trading to commence on the OTCQB Venture Market in the US |
+2.9% | |
| 30 Mar 26 | £4.8m contracts awarded
£4.8m contracts awarded for development of multiplex lateral flow systems |
+10.3% | |
| 17 Mar 26 | Results | Half-year Results
45% revenue growth, H2 to be profitable and cash flow positive, confident outlook for FY27 |
−3.0% |
| 12 Mar 26 | $2.5m Contract for clinical self-test development
$2.5m Contract Award for development of clinical self-test |
+3.1% | |
| 10 Mar 26 | Trading on the OTCQB Venture Market in the US
Trading on the OTCQB Venture Market in the US |
+6.9% | |
| 05 Mar 26 | Routine | Notice of Results | |
| 15 Jan 26 | Trading update | Trading Update
15 January 2026: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, provides its half-year trading update for the si |
+0.0% |
| 15 Jan 26 | Appointment of NOMAD & Corporate Broker
15 January 2026: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces the appointment of Cavendish Capital M |
+0.0% | |
| 29 Dec 25 | Routine | Exercise of options and total voting rights | |
| 18 Dec 25 | European patent for AppDx® smartphone reader
European patent for AppDx® lateral flow smartphone reader |
+0.0% | |
| 10 Dec 25 | Routine | Result of AGM | |
| 04 Dec 25 | Vesting and Award of Options under LTIP
York, UK 4 December 2025: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces updates, under the terms of t |
+0.0% | |
| 02 Dec 25 | Holding | Holding(s) in Company | |
| 14 Nov 25 | Routine | Notice of AGM & Publication of 2025 Annual Report | |
| 11 Nov 25 | Results | Final Results
Final Results for the financial year ended 30 June 2025 |
−7.1% |
| 10 Nov 25 | C.US$2m multiplex diagnostic test contract win
Development, scale-up and technical transfer for a semi-quantitative, multiplex lateral flow test system |
+15.9% | |
| 06 Nov 25 | Launch of seaweed-based lateral flow housings
Alternative to standard plastic housings to reduce plastic waste from LFTs |
+1.4% | |
| 04 Nov 25 | Holding | Holding(s) in Company | |
| 04 Nov 25 | Holding | Holding(s) in Company | |
| 03 Nov 25 | Routine | Notice of Results | |
| 30 Oct 25 | Routine | Result of Meeting and TVR | |
| 17 Oct 25 | Fundraise | Result of Retail Offer
TERMS NOT OTHERWISE DEFINED HEREIN SHALL HAVE THE MEANINGS GIVEN TO THEM IN THE COMPANY'S ANNOUNCEMENT RELEASED ON 13 OCTOBER 2025 AT 5:04PM. |
+0.0% |
| 14 Oct 25 | Fundraise | Launch of Retail Offer
Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces a retail offer via BookBuild (the "Retail Offer") of ne |
+3.3% |
| 14 Oct 25 | Fundraise | Result of Placing and Notice of GM
THIS ANNOUNCEMENT SHOULD BE READ IN ITS ENTIRETY. |
+3.3% |
| 13 Oct 25 | Fundraise | Proposed Placing and Retail Offer
ZEUS CAPITAL LIMITED ("ZEUS"), WHICH IS AUTHORISED AND REGULATED IN THE UNITED KINGDOM BY THE FINANCIAL CONDUCT AUTHORITY, IS ACTING FOR THE COMPANY AND FOR NO-ONE ELSE IN CONNECTION WITH THE PLACING, AND ZEUS WILL NOT B |
+0.0% |
Company filings. Not investment advice.